Taysha gene therapies announces proposed public offering of common stock

Dallas, oct. 25, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced that it intends to offer and sell, subject to market conditions, $30 million of shares of its common stock in an underwritten public offering. all shares of common stock to be sold in the offering will be offered by taysha. taysha also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions. the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
TSHA Ratings Summary
TSHA Quant Ranking